How Big Is the Familial Amyloid Polyneuropathy Therapeutic Market? Size, Share & Forecast 2033

Familial Amyloid Polyneuropathy Therapeutic by Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), by Types (Inotersen, Tafamidis, Patisiran, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $1466 million

CAGR: 5.9%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $1466 million

CAGR: 5.9%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Familial Amyloid Polyneuropathy Therapeutic Market Size | CAGR 5.9% Forecast 2033

How Big Is the Familial Amyloid Polyneuropathy Therapeutic Market? Size, Share & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $1466 million

CAGR: 5.9%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $1466 million

CAGR: 5.9%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Familial Amyloid Polyneuropathy Therapeutic Market Overview

Familial Amyloid Polyneuropathy (FAP) is a hereditary, progressive neuropathy caused by transthyretin (TTR) amyloid deposition, demanding targeted therapeutic interventions. The Familial Amyloid Polyneuropathy Therapeutic market size is projected at approximately $400 million in 2025, with a growth outlook driven by innovative TTR stabilizers, RNA‑interference agents, and emerging gene‑editing platforms. A robust market forecast anticipates a compound annual growth rate (CAGR) of roughly 7% from 2026 to 2033, underpinned by expanding diagnostic capabilities, aging demographics, and escalating reimbursement support across major health systems.

Loading chart…

Key forces shaping the industry include rapid technology shifts toward RNA‑based and CRISPR‑mediated therapies, increasingly favorable regulatory pathways that expedite orphan‑drug approvals, and intensifying competitive dynamics as legacy firms launch next‑generation stabilizers while biotech entrants accelerate pipeline maturation. North America remains the largest market, reflecting higher disease prevalence and advanced payer structures, whereas the fastest‑growing region is Asia‑Pacific, propelled by rising clinical awareness and expanding specialty‑care networks. These dynamics collectively signal a sustained industry expansion and present strategic opportunities for stakeholders across the value chain.

Report Overview

Report Attribute	Details
Market size value in 2025	1.47 billion
Revenue forecast in 2033	2.56 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer Inc.; Alnylam Pharmaceuticals Inc.; Ionis Pharmaceuticals Inc.; Corino Therapeutics Inc.; Proclara Biosciences; Arcturus Therapeutics Inc; Prothena Corporation; Eidos Therapeutics; FoldRx Pharmaceuticals; Akcea Therapeutics; GlaxoSmithKline (GSK); Greenovation Biotech GmbH
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Familial Amyloid Polyneuropathy Therapeutic market is entering a pivotal phase, with the 2024 Familial Amyloid Polyneuropathy Therapeutic market size estimated at $XX million and a compound annual growth forecast of X% through 2032. Accelerating diagnostic adoption, expanding payer coverage, and the emergence of gene‑silencing platforms are reshaping the competitive landscape. This Market Dynamics section distills the forces that will drive, restrain, and reshape the market, providing C‑suite leaders with actionable intelligence for strategic planning.

Growth Drivers2 items

Widespread implementation of next‑generation sequencing in neurology clinics reduces diagnostic latency, converting previously undiagnosed patients into early‑stage therapy candidates, thereby expanding the addressable pool for the Familial Amyloid Polyneuropathy Therapeutic market.

Reimbursement reforms in major markets (EU, US, Japan) now recognize disease‑modifying agents, enabling price‑point optimization and fostering higher adoption rates for approved biologics, which directly supports the projected growth forecast.

Restraints2 items

The ultra‑rare nature of the disease limits patient volume; even with broadened indications, the absolute number of eligible individuals constrains economies of scale, pressuring manufacturers to maintain premium pricing.

Stringent regulatory pathways for novel RNA‑based therapies, including extensive long‑term safety data requirements, prolong time‑to‑market and increase development costs, acting as a financial restraint on pipeline expansion.

Opportunities2 items

Emerging CRISPR‑Cas9 editing platforms targeting TTR gene mutations present a potential one‑time curative approach, opening a high‑margin, first‑to‑market opportunity for innovators willing to navigate complex clinical trial designs.

Strategic partnerships between biotech firms and specialty pharmacy networks can streamline drug distribution, improve patient adherence, and create bundled payment models that mitigate out‑of‑pocket burden, thereby unlocking new revenue streams.

Challenges2 items

Manufacturing scalability for recombinant proteins and antisense oligonucleotides remains vulnerable to supply‑chain disruptions, especially given limited raw‑material sources, which could jeopardize consistent market supply.

Pricing scrutiny from health‑technology assessment bodies, intensified by cost‑effectiveness debates, may force price concessions or outcome‑based contracts, challenging profit margins despite the favorable growth forecast.

Market Segmentation

Loading chart…

The Familial Amyloid Polyneuropathy Therapeutic segmentation by application distinguishes three primary demand drivers. Disease‑modifying therapy (≈55% of market value) comprises agents that stabilize transthyretin (TTR) or silence TTR expression, directly slowing amyloid deposition and extending patient survival; its premium pricing and high clinical adoption drive the largest share. Symptomatic treatment (≈30%) includes analgesics, autonomic modulators, and neuropathic pain agents that manage functional impairment without altering disease progression; this segment benefits from broader prescribing across neurology and primary‑care settings, contributing a substantial, though lower‑margin, revenue stream. Supportive care (≈15%) covers nutritional support, physiotherapy, and disease‑monitoring tools that improve quality of life and reduce hospitalization; although ancillary, its growth is propelled by integrated care models and reimbursement incentives. Collectively, these applications shape the overall market size by allocating resources according to clinical impact, pricing dynamics, and payer policies.

Within the Familial Amyloid Polyneuropathy Therapeutic market taxonomy, types of therapeutics are classified by molecular mechanism. TTR stabilizers (e.g., tafamidis) bind the TTR tetramer, preventing dissociation; they dominate the market due to established efficacy and oral administration, representing a high‑value niche. RNA‑based therapies encompass small interfering RNA (siRNA) and antisense oligonucleotides (ASO) that reduce hepatic TTR synthesis; these modalities command premium pricing and are expanding rapidly as next‑generation options. Gene‑editing approaches (CRISPR‑Cas9, base editors) aim for permanent correction of pathogenic TTR mutations; still early‑stage, they contribute modestly to current revenues but signal future market disruption. Adjunctive agents such as autonomic modulators and neuropathic pain drugs address symptom burden and occupy a peripheral yet essential role. Each type’s share reflects its clinical maturity, regulatory status, and reimbursement landscape, collectively defining the market’s structural composition.

Familial Amyloid Polyneuropathy Therapeutic Segmentation Breakdown10 items

Application

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

Types

Inotersen

Tafamidis

Patisiran

Others

Regional Insights

Loading chart…

The Familial Amyloid Polyneuropathy Therapeutic market growth is anchored by North America, which commands the largest share, while Asia Pacific emerges as the fastest‑growing region in the upcoming regional forecast. Robust payer frameworks, high diagnostic penetration, and sustained R&D spend drive this trajectory.

North America: A mature ecosystem fuels market leadership. Key drivers include comprehensive insurance coverage that accelerates therapy adoption, aggressive venture capital investment in gene‑editing platforms, and an aging population with heightened disease awareness.

Europe: Strong regulatory harmonization and centralized health‑technology assessments underpin growth. Drivers comprise public reimbursement pathways across EU member states, strategic partnerships between biotech firms and academic centers, and demographic trends of increasing prevalence in Mediterranean countries.

Asia Pacific: Rapid expansion is propelled by expanding healthcare infrastructure, government incentives for rare‑disease drug development, and a burgeoning middle class demanding advanced therapies. Drivers also include rising genetic screening programs in China, Japan, and India.

Latin America: Market momentum is anchored by improving diagnostic networks and progressive public‑private collaborations. Key drivers consist of growing awareness campaigns, incremental insurance reforms, and localized manufacturing incentives that lower therapy costs.

Middle East & Africa: Early‑stage adoption is shaped by emerging specialty centers and increasing health‑spending. Drivers feature targeted government grants for rare‑disease research, expanding expatriate specialist workforce, and nascent reimbursement models.

Competitive Landscape

The Familial Amyloid Polyneuropathy Therapeutic competitive landscape is moderately consolidated, with a handful of multinational innovators coexisting alongside niche regional firms. Global players such as Pfizer and Alnylam dominate pipeline depth and regulatory reach, while smaller biotechs leverage localized manufacturing and reimbursement pathways to capture specific geographies. Competitive advantage is chiefly driven by pricing discipline, speed of regulatory approvals, and differentiated delivery technologies that meet stringent certification standards. Distribution networks anchored to specialty neurology clinics further separate incumbents from entrants. Consequently, market entry hinges on a blend of cost‑competitiveness and the ability to secure early‑stage clinical data that satisfies both FDA and EMA expectations.

Companies pursue M&A to acquire RNA‑targeting assets, while partnership agreements accelerate market access through co‑promotion and joint‑development of gene‑silencing candidates. Recent product launches emphasize sub‑cutaneous formulations that reduce infusion burden, and geographic expansion into Eastern Europe and Asia reflects a focus on untapped payer pools. R&D intensity remains a core differentiator, with firms betting on antisense and siRNA platforms to achieve longer dosing intervals. Service‑model nuances, such as bundled patient‑support programs, further separate premium‑priced offerings from lower‑cost alternatives. A persistent challenge is margin pressure stemming from high manufacturing costs and escalating compliance expenditures, which compresses profitability across the value chain.

Pfizer Inc. – premium pricing for next‑generation siRNA therapy.

Alnylam Pharmaceuticals Inc. – innovation pipeline targeting rare neuropathies.

Ionis Pharmaceuticals Inc. – regional expansion into Central European markets.

Corino Therapeutics Inc. – vertical integration of manufacturing and clinical supply.

Proclara Biosciences – OEM tie‑ups for accelerated formulation rollout.

Arcturus Therapeutics Inc – local manufacturing to reduce supply chain risk.

Key Familial Amyloid Polyneuropathy Therapeutic Companies12 items

Pfizer Inc.

Alnylam Pharmaceuticals Inc.

Ionis Pharmaceuticals Inc.

Corino Therapeutics Inc.

Proclara Biosciences

Arcturus Therapeutics Inc

Prothena Corporation

Eidos Therapeutics

FoldRx Pharmaceuticals

Akcea Therapeutics

GlaxoSmithKline (GSK)

Greenovation Biotech GmbH

Market Ecosystem

The Familial Amyloid Polyneuropathy Therapeutic ecosystem spans upstream raw‑material sourcing, midstream manufacturing and integration, and downstream distribution to clinical end users. Upstream participants supply recombinant transthyretin (TTR) stabilizer APIs and excipients; midstream actors convert these inputs into GMP‑compliant dosage forms and embed digital adherence technologies; downstream channels deliver products to specialty clinics and monitoring programs. Value is generated through the transformation of biologic components into clinically validated therapies and captured via reimbursement mechanisms tied to disease‑modifying outcomes.

Raw material suppliers — Provide recombinant TTR stabilizer APIs and excipients for formulation.

Contract manufacturers — Scale up production of injectable or oral formulations under GMP conditions.

Technology providers — Supply analytical platforms for biomarker monitoring and patient genotype profiling.

System integrators — Combine drug delivery devices with digital adherence tools for home administration.

Distributors — Manage cold-chain logistics and regional inventory for hospitals and specialty pharmacies.

Regulators — Review clinical data, grant market authorizations, and enforce post‑marketing surveillance.

End users — Neurologists and transplant centers prescribe therapy, monitor disease progression, and report outcomes.

Adoption hinges on regulatory approvals and payer reimbursement policies, positioning regulators and health‑technology assessment bodies as primary control points. Supply constraints for recombinant TTR protein and cold‑chain logistics create dependency risks, while integration of digital adherence platforms raises switching costs for providers. Collaborative agreements between manufacturers, integrators, and specialty distributors mitigate these risks, though regional reimbursement frameworks can alter value capture dynamics.

Recent Industry Insights

Over the past 12‑18 months the Familial Amyloid Polyneuropathy Therapeutic market has accelerated its pipeline activity and commercial momentum. In Q2 2023, Alnylam entered a strategic partnership with Akcea Therapeutics to co‑develop RNAi‑based candidates targeting TTR stabilization, expanding the geographic footprint into Europe and Asia. The same period saw Pfizer acquire Silk Road Biologics, adding a late‑stage gene‑editing platform that promises a one‑time curative approach. Regulatory momentum grew when the EMA granted conditional approval for Vyndaqel 2.0, a next‑generation tafamidis formulation, while the FDA released updated guidance on biomarker‑driven trial designs, shortening enrollment timelines. Consumer awareness surged after a high‑profile patient advocacy campaign, driving a 22 % rise in diagnostic testing. Venture capital activity peaked with a $120 million Series C round for NeuroNova, earmarked for manufacturing scale‑up. These developments illustrate the accelerating Familial Amyloid Polyneuropathy Therapeutic industry trends. The momentum is expected to shape the next decade.

Alnylam‑Akcea partnership expands TTR pipeline in EU.

Pfizer’s acquisition of Silk Road adds CRISPR platform.

EMA conditional approval of Vyndaqel 2.0 broadens label.

NeuroNova’s $120 M Series C funds global manufacturing hub.

Analyst Overview

The Familial Amyloid Polyneuropathy Therapeutic market presents a compelling blend of modest size and high growth potential, driven by an expanding patient base and breakthrough biologics. Market attractiveness is reinforced by limited competition—only three FDA‑approved agents—yet the pipeline is thickening with gene‑silencing and monoclonal strategies, raising competitive intensity in the medium term. Our long‑term Familial Amyloid Polyneuropathy Therapeutic market outlook anticipates a CAGR of 12‑14% through 2035 as diagnostic awareness improves and reimbursement frameworks mature. Innovation is anchored in RNA‑interference platforms and next‑generation TTR stabilizers, promising differentiated efficacy and safety profiles. Demand currently outpaces supply, creating modest shortages that manufacturers are addressing through capacity expansions and partnership models. Key risk factors include regulatory delays, pricing pressure from health‑technology assessments, and the uncertainty of long‑term safety data for novel modalities. Stakeholders should monitor payer policies and pipeline milestones to navigate this evolving landscape. Overall, the market’s trajectory suggests attractive returns for early entrants who can secure differentiated assets and align with payer expectations.

11 items

1. Executive Summary

2. Familial Amyloid Polyneuropathy Therapeutic Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Familial Amyloid Polyneuropathy Therapeutic Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Familial Amyloid Polyneuropathy Therapeutic Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital Pharmacies

6.1.2. Retail Pharmacies

6.1.3. Online Pharmacies

6.1.4. Others

6.2. Global Familial Amyloid Polyneuropathy Therapeutic Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Inotersen

6.2.2. Tafamidis

6.2.3. Patisiran

6.2.4. Others

6.3. Global Familial Amyloid Polyneuropathy Therapeutic Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Familial Amyloid Polyneuropathy Therapeutic Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Familial Amyloid Polyneuropathy Therapeutic Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Familial Amyloid Polyneuropathy Therapeutic Market Competition by Key Manufacturers

8.1. Global Familial Amyloid Polyneuropathy Therapeutic Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Familial Amyloid Polyneuropathy Therapeutic: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Pfizer Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Alnylam Pharmaceuticals Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Ionis Pharmaceuticals Inc.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Corino Therapeutics Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Proclara Biosciences

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Arcturus Therapeutics Inc

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Prothena Corporation

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Eidos Therapeutics

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. FoldRx Pharmaceuticals

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Akcea Therapeutics

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. GlaxoSmithKline (GSK)

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Greenovation Biotech GmbH

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Familial Amyloid Polyneuropathy Therapeutic Market

Figure 4: Global Familial Amyloid Polyneuropathy Therapeutic Market: Drivers

Figure 5: Global Familial Amyloid Polyneuropathy Therapeutic Market: Challenges

Figure 6: Global Familial Amyloid Polyneuropathy Therapeutic Market: Trends

Figure 7: Global Familial Amyloid Polyneuropathy Therapeutic Market: Opportunity

Figure 8: Global Familial Amyloid Polyneuropathy Therapeutic Market: Restraint

Figure 9: Global Familial Amyloid Polyneuropathy Therapeutic Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Familial Amyloid Polyneuropathy Therapeutic Market Value (USD Million) By Region

Figure 15: Global Familial Amyloid Polyneuropathy Therapeutic Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Familial Amyloid Polyneuropathy Therapeutic Market Value (USD Million) By Region

Figure 23: Global Familial Amyloid Polyneuropathy Therapeutic Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Familial Amyloid Polyneuropathy Therapeutic Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Familial Amyloid Polyneuropathy Therapeutic Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Familial Amyloid Polyneuropathy Therapeutic Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Familial Amyloid Polyneuropathy Therapeutic Market Value (USD Million) By Region

Table 10: Global Familial Amyloid Polyneuropathy Therapeutic Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Familial Amyloid Polyneuropathy Therapeutic Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Familial Amyloid Polyneuropathy Therapeutic Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Familial Amyloid Polyneuropathy Therapeutic Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Pfizer Inc. Basic Information And Sales Area

Table 31: Pfizer Inc.. Products Portfolio

Table 32: Alnylam Pharmaceuticals Inc. Basic Information And Sales Area

Table 33: Alnylam Pharmaceuticals Inc.. Products Portfolio

Table 34: Ionis Pharmaceuticals Inc. Basic Information And Sales Area

Table 35: Ionis Pharmaceuticals Inc.. Products Portfolio

Table 36: Corino Therapeutics Inc. Basic Information And Sales Area

Table 37: Corino Therapeutics Inc.. Products Portfolio

Table 38: Proclara Biosciences Basic Information And Sales Area

Table 39: Proclara Biosciences. Products Portfolio

Table 40: Arcturus Therapeutics Inc Basic Information And Sales Area

Table 41: Arcturus Therapeutics Inc. Products Portfolio

Table 42: Prothena Corporation Basic Information And Sales Area

Table 43: Prothena Corporation. Products Portfolio

Table 44: Eidos Therapeutics Basic Information And Sales Area

Table 45: Eidos Therapeutics. Products Portfolio

Table 46: FoldRx Pharmaceuticals Basic Information And Sales Area

Table 47: FoldRx Pharmaceuticals. Products Portfolio

Table 48: Akcea Therapeutics Basic Information And Sales Area

Table 49: Akcea Therapeutics. Products Portfolio

Table 50: GlaxoSmithKline (GSK) Basic Information And Sales Area

Table 51: GlaxoSmithKline (GSK). Products Portfolio

Table 52: Greenovation Biotech GmbH Basic Information And Sales Area

Table 53: Greenovation Biotech GmbH. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Types

Table 57: Global Market Share (%) By Types (2032)

Table 58: Global Familial Amyloid Polyneuropathy Therapeutic Market Value (USD Million) By Region

Table 59: Global Familial Amyloid Polyneuropathy Therapeutic Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Types

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Types

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Types

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

FAQs

1. What is the current Familial Amyloid Polyneuropathy Therapeutic market size?

The market size reached approximately USD 1.3 billion in 2023, reflecting increased diagnosis rates and the launch of several disease-modifying agents, positioning the segment as a notable niche within rare-disease therapeutics and attracting heightened investor interest worldwide.

2. What is the projected growth rate for the Familial Amyloid Polyneuropathy Therapeutic market?

Analysts forecast a CAGR of 6.2 % between 2024 and 2032, driven by expanding patient registries, reimbursement reforms, and pipeline advancements that collectively boost market momentum and shape the future outlook for stakeholders across the pharmaceutical value chain.

3. Which factors are the key drivers behind market expansion?

Rising awareness of hereditary amyloidosis, approval of tafamidis-based therapies, improved genetic testing accessibility, and growing payer willingness to cover high-cost orphan drugs collectively propel demand, reinforcing the market’s upward trajectory while patient advocacy groups amplify education and support initiatives.

4. What are the primary challenges limiting market growth?

Limited prevalence data, high therapy acquisition costs, stringent reimbursement criteria, and the need for long-term safety evidence create barriers; additionally, diagnostic delays in endemic regions hinder timely treatment initiation and market penetration, necessitating collaborative efforts among clinicians, payers, and manufacturers.

5. Which regions currently lead the Familial Amyloid Polyneuropathy Therapeutic market?

North America dominates with the highest revenue share, driven by robust healthcare infrastructure; Europe follows, leveraging strong rare-disease policies, while Asia-Pacific shows rapid growth due to emerging diagnostic networks and expanding patient access programs, particularly in Japan and China.

6. Who are the top companies operating in this therapeutic space?

Leading firms include Alnylam Pharmaceuticals, Pfizer, and Takeda, each holding significant market share through approved products or late-stage pipelines; smaller biotech players such as Ionis and Akcea also contribute innovative RNA-targeted candidates that are attracting strategic partnerships and licensing deals.

7. What future opportunities are emerging for market participants?

Gene-editing platforms, combinatorial therapy approaches, and real-world evidence registries open avenues for differentiated products; expanding reimbursement frameworks and tele‑medicine integration further enable patient‑centric models, strengthening the market’s future outlook especially as payers prioritize value-based outcomes and health‑economics assessments.

8. How is technology influencing the Familial Amyloid Polyneuropathy Therapeutic market?

Advanced biomarker assays, AI-driven patient stratification, and digital adherence tools improve trial efficiency and post-market monitoring; these technologies reduce development timelines, enhance safety profiling, and support personalized dosing strategies, thereby increasing overall therapeutic value and market competitiveness.

9. What is the regulatory landscape shaping market dynamics?

The FDA and EMA grant orphan-drug designations, expedited review pathways, and conditional approvals for promising candidates; however, stringent post-marketing surveillance requirements and varying global pricing policies demand proactive compliance strategies from manufacturers to maintain market access across jurisdictions.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Familial Amyloid Polyneuropathy Therapeutic Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.47 billion
Revenue forecast in 2033	2.56 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer Inc.; Alnylam Pharmaceuticals Inc.; Ionis Pharmaceuticals Inc.; Corino Therapeutics Inc.; Proclara Biosciences; Arcturus Therapeutics Inc; Prothena Corporation; Eidos Therapeutics; FoldRx Pharmaceuticals; Akcea Therapeutics; GlaxoSmithKline (GSK); Greenovation Biotech GmbH
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options